6,292 Shares in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,292 shares of the biotechnology company’s stock, valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. owned 0.13% of Atara Biotherapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Delap Wealth Advisory LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth $29,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the second quarter worth $79,000. BNP Paribas Financial Markets grew its position in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares in the last quarter. Acadian Asset Management LLC grew its position in Atara Biotherapeutics by 49.5% in the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after purchasing an additional 873,133 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after purchasing an additional 4,903,159 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their target price for the company from $25.00 to $18.00 in a research report on Friday, August 16th. The Goldman Sachs Group decreased their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday, June 26th. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $13.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $14.00.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $7.69 on Friday. The firm has a 50-day moving average of $8.01 and a 200-day moving average of $11.92. Atara Biotherapeutics, Inc. has a one year low of $4.96 and a one year high of $45.75. The company has a market cap of $37.04 million, a PE ratio of -0.14 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The firm had revenue of $28.64 million for the quarter, compared to the consensus estimate of $48.30 million. Analysts expect that Atara Biotherapeutics, Inc. will post -12.09 earnings per share for the current year.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.